Peptide mixture
There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.
1. A method of stimulating the immune system in a human or animal subject with cancer, wherein the cancer is associated with RAS protein amino acid substitutions, the method comprising administering to the subject a peptide mixture suitable for eliciting an immune response in a human or animal subject with cancer, wherein the peptide mixture comprises a first, second, third, fourth, fifth and sixth peptide, each corresponding to a fragment of the RAS protein,
wherein the first, second, third, fourth, fifth and sixth peptides are:
a peptide comprising the amino acid sequence of SEQ ID NO: 27,
a peptide comprising the amino acid sequence of SEQ ID NO: 28,
a peptide comprising the amino acid sequence of SEQ ID NO: 29,
a peptide comprising the amino acid sequence of SEQ ID NO: 30,
a peptide comprising the amino acid sequence of SEQ ID NO: 31, and
a peptide comprising the amino acid sequence of SEQ ID NO: 32, and
wherein each of the peptides comprises no more than 30 amino acids, in order to elicit an immune response in the subject.
2. A method according to claim 1 , wherein the method comprises the step of identifying RAS protein amino acid substitutions in the subject before administering the peptide mixture.
3. A method according to claim 1 , wherein the method comprises administering to the subject a pharmaceutical composition comprising the peptide mixture and pharmaceutically acceptable carrier, diluent and/or excipient.
4. A method according to claim 1 , wherein the cancer is selected from the group consisting of adrenal gland, autonomic ganglia, biliary tract, bone, breast, central nervous system, cervical, colorectal, endometrial, haematopoietic, lymphoid, kidney, large intestine, liver, lung, oesophagus, ovarian, pancreatic, prostate, salivary gland, skin, small intestine, stomach, testicular, thymus, thyroid, upper aerodigestive tract, urinary tract cancer, malignant melanoma and combinations thereof.
5. A method according to claim 4 , wherein the cancer is selected from the group consisting of colorectal, lung, pancreatic cancer and combinations thereof.